Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
PPHMP was delisted on the 5th of January, 2018.
1 hedge funds and large institutions have $4.34M invested in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
9% more capital invested
Capital invested by funds: $3.99M → $4.34M (+$348K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWA
Burt Wealth Advisors
North Bethesda,
Maryland
|
-$12K |
PPHMP Hedge Fund Activity: Q1 2017 in Review
1 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) for Q1 2017, worth a combined $4.34M — up 8.7% from $3.99M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PPHMP and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Burt Wealth Advisors, exiting entirely with an estimated $12K sold.
- 1 institutional investor held Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) as of Q1 2017, down from 2 in Q4 2016.
- Funds reported $4.34M of Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible stock for Q1 2017, up 8.7% quarter-over-quarter.
- 0 funds opened new Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible positions in Q1 2017 and 1 closed out, a net change of -1 holder.
- The largest Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible seller in Q1 2017 was Burt Wealth Advisors, an estimated $12K sold.
Based on aggregated 13F filings for Q1 2017.